Skip to main content
S&P 5007,799.58-0.25%DOW51,181.62-0.66%NASDAQ27,506.69-0.34%BTC$83,360.00-2.42%ETH$2,560.81-4.68%GOLD$4,133.20-1.29%OIL$88.91-0.59%
Smart Investors Daily
SID Premium
HR

NASDAQ · HRMY

Harmony Biosciences Holdings, Inc.

Healthcare · Biotechnology

$39.36

Up+$0.25 (+0.64%)

Updated Oct 7, 2026, 7:15 PM

SID Score

7.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.28B
P/E ratio
12.47
Dividend yield
0.00%
52-week range
$26.34 – $43.49
Volume
507.28K
Avg. volume
922.99K

Price performance · HRMY

HRMY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

HRMY closed at $39.36 after 21 trading sessions, down 6.44% for the selected period.

Last close
$39.36
Period change
-6.44%
Period low
$39.26
Period high
$42.74
Daily close
View OHLC price history
HRMY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$40.09$40.35$38.91$39.36507.28K
Oct 5, 2026$39.76$40.77$39.51$39.92897.92K
Oct 2, 2026$39.78$40.6179$39.25$39.64916.73K
Oct 1, 2026$39.58$40.46$39.076$39.571.23M
Sep 30, 2026$39.30$39.555$38.72$39.26667.69K
Sep 29, 2026$39.87$40.518$39.15$39.29786.68K
Sep 28, 2026$41.29$41.535$39.535$40.01874.39K
Sep 25, 2026$41.37$41.60$40.89$41.26557.01K
Sep 24, 2026$40.63$41.79$40.00$41.16906.46K
Sep 23, 2026$41.61$42.08$39.715$40.481.08M
Sep 22, 2026$42.10$42.37$41.36$41.53577.96K
Sep 21, 2026$41.87$42.5199$41.20$42.10839.02K
Sep 18, 2026$42.57$43.27$41.90$42.023.82M
Sep 17, 2026$42.59$43.01$42.10$42.74641.41K
Sep 16, 2026$42.28$43.05$42.06$42.211.6M
Sep 15, 2026$41.64$42.19$40.9358$42.171.21M
Sep 14, 2026$41.93$42.25$41.48$41.541.04M
Sep 11, 2026$41.30$41.72$40.9195$41.521.12M
Sep 10, 2026$41.26$41.7208$40.93$41.10736.83K
Sep 9, 2026$42.01$42.405$41.23$41.621.13M
Sep 8, 2026$42.20$43.25$41.555$42.071.78M

Latest HRMY news

The latest Smart Investors Daily articles mentioning HRMY.

Stock researchCompany · Overview

HRMY research

Overview

Company profile and research snapshot.

Company profile

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$47.80
Implied upside
—
Analysts
17
HRMY recent ratings
DateFirmRatingTarget
Aug 26, 2026Wolfe ResearchOutperform—
Aug 5, 2026Truist SecuritiesHold—
Aug 4, 2026NeedhamBuy—
Jul 31, 2026MizuhoOutperform—
Jul 16, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland. Poster details are listed below: Abstract Title:Phase 3, randomized, double-blind,

Yahoo · Sep 3, 2026

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece. The company is investigating EPX-100 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome in the ongoing ARGUS and LIGHTHOUSE trials, respectively. These trials are current

Yahoo · Aug 27, 2026

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony BiosciencesHarmony Biosciences

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By